Dexcom selects Ireland for first European manufacturing site
Dexcom, a global leader in continuous glucose monitoring for people with diabetes, plans to build its newest global manufacturing facility in Athenry, County Galway. The project is supported by the Irish Government through IDA Ireland and represents an investment of €300 million over five years and the potential to create up to 1,000 high skilled jobs over the same period.
Subject to planning permission, the Ireland site will be Dexcom’s first manufacturing site in Europe, expanding upon the company’s existing capabilities in the U.S. and Malaysia. The new facility will have the capacity to produce millions of Dexcom CGM sensors each year, helping to improve the lives of people with diabetes around the world. Subject to planning approval, the new facility will be located on the IDA Ireland strategic landbank in Athenry.
The facility in Athenry will contain a highly automated and efficient manufacturing operation with an emphasis on green technologies. Dexcom expects to provide about 500 construction jobs while the facility is being built and up to 1,000 high tech graduate and technician level positions once the site is running at full capacity.
“With the continued success of our Dexcom G7 in Europe, we are pursuing an ambitious growth strategy that requires increased manufacturing capacity to support our rapidly expanding European user base,” said Barry Regan, Executive Vice President of Global Operations at Dexcom. “Ireland has an exceptional talent pool and an established MedTech sector, making Athenry the perfect location for us to establish a new, state-of-the-art manufacturing facility.”
“This is an important strategic investment by Dexcom in Athenry, Co Galway, a regional location that will greatly benefit from the widespread economic and employment boost that an announcement such as this has the potential to deliver,” said Michael Lohan, CEO of IDA Ireland. “Ireland’s track record in attracting MedTech investments from major innovators, speaks for itself. This latest investment only enhances that further. I wish Dexcom every success with this investment and assure them of IDA Ireland’s continued support.”
In October 2022, Ireland was one of the initial launch markets globally for Dexcom G7, the company’s next-generation CGM system that offers a powerful yet simple way to help people gain greater control of their diabetes. The system’s low-profile, all-in-one wearable sends real-time glucose readings automatically to a compatible smart device or receiver, no painful finger sticks or burdensome scanning required. Dexcom G7 builds on the trusted performance of Dexcom CGM, which is clinically proven to lower A1C and reduce hyper- and hypoglycemia.
For information about Dexcom job openings in Athenry go to: careers.dexcom.com/careers
CAPTION:
Pictured (left to right): Michael Lohan, CEO of IDA Ireland; Minister for Enterprise Trade & Employment Simon Coveney TD; and Barry Regan, Executive Vice President of Global Operations at Dexcom.
